[Pharmacological characteristics and clinical efficacy of bosentan].
Fujimoto
Kazumi
K
Kazumi.Fujimoto@actelion.com
Ikenoya
Satoru
S
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000077300:Bosentan; D004195:Disease Models, Animal; D064420:Drug-Related Side Effects and Adverse Reactions; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000517:prevention & control; D066298:In Vitro Techniques; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D014661:Vasoconstriction / Q000187:drug effects
D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1; D013449:Sulfonamides; D019001:Nitric Oxide Synthase; D000077300:Bosentan